http://www.fiercebiotech.com/story/takeda-heads-back-fda-diabetes-blockbuster-hopeful/2011-07-26
"If approved, alogliptin/pioglitazone will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione in a single tablet."
http://www.fiercebiotech.com/press-...ications-investigational-type-2-diabetes-ther
"If approved, alogliptin/pioglitazone will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione in a single tablet."
http://www.fiercebiotech.com/press-...ications-investigational-type-2-diabetes-ther
